Valuation: Insulet Corporation

Market Cap 10.39B 9.33B 8.61B 7.81B 14.6B 987B 14.77B 103B 41B 517B 39.01B 38.17B 1,641B P/E 2026 *
24.5x
P/E 2027 * 19.6x
Enterprise Value 10.44B 9.37B 8.65B 7.85B 14.66B 992B 14.84B 104B 41.2B 520B 39.19B 38.35B 1,648B EV / Sales 2026 *
3.18x
EV / Sales 2027 * 2.7x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.38%
1 week+5.04%
Current month+14.84%
1 month+10.06%
3 months-9.19%
6 months-20.43%
Current year-47.29%
1 week 142.47
Extreme 142.47
150.74
1 month 128.01
Extreme 128.01
150.74
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 126.4
Extreme 126.4
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Director/Board Member 61 27/07/2015
Director/Board Member 54 20/10/2020
Director/Board Member 55 18/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Tax

Chief Financial Officer

-1,882 0.0027%
30/9/26 Free

Director

141 0.0002%
30/9/26 Free

Director

178 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%+5.04%-54.01%+12.29% 10.39B
-1.70%+0.63%-18.93%+11.04% 178B
-1.54%-0.98%-21.45%+15.09% 116B
-0.89%-0.72%-0.19%+35.32% 115B
+3.89%+20.80%-42.56%+8.20% 93.1B
-1.40%-5.21%-3.18%+73.40% 62.09B
+0.17%-0.51%+10.68%+84.08% 55.87B
-0.69%+0.63%+4.27%-22.48% 53.12B
-1.57%+0.60%-13.31%+43.41% 44.22B
-0.66%+3.26%-4.83%-8.81% 33.59B
Average -0.42%+2.55%-14.35%+25.15% 76.14B
Weighted average by Cap. -0.57%+2.41%-13.83%+24.10%

Financials

2026 *2027 *
Net sales 3.29B 2.95B 2.72B 2.47B 4.62B 312B 4.67B 32.66B 12.97B 164B 12.34B 12.07B 519B 3.73B 3.35B 3.09B 2.81B 5.24B 355B 5.31B 37.09B 14.73B 186B 14.01B 13.71B 589B
Net income 425M 382M 352M 320M 597M 40.39B 605M 4.22B 1.68B 21.17B 1.6B 1.56B 67.13B 534M 479M 442M 401M 750M 50.71B 759M 5.3B 2.11B 26.58B 2B 1.96B 84.29B
Net Debt 49.62M 44.54M 41.12M 37.29M 69.7M 4.71B 70.55M 493M 196M 2.47B 186M 182M 7.83B -322M -289M -267M -242M -453M -30.62B -458M -3.2B -1.27B -16.05B -1.21B -1.18B -50.9B
Projected Income Statement - Annual - Insulet Corporation
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
27/10/26 USD 149.83 +0.38% 943,833
26/10/26 USD 149.26 +0.17% 1,525,635
23/10/26 USD 149.01 +0.60% 803,141
22/10/26 USD 148.12 +4.38% 1,213,882
21/10/26 USD 141.90 -0.52% 1,046,227
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Insulet Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
149.83USD
Average target price
167.17USD
Spread / Average Target
+11.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insulet Corporation
  1. Stock Market
  2. Stocks
  3. PODD Stock